Toll-Like Receptor 9 Agonist Applications in Cancer Immunotherapy

Toll-like receptor 9 (TLR9) agonists have emerged as versatile modulators of innate immunity with the capacity to bridge to adaptive antitumour responses. By engaging endosomal TLR9 on plasmacytoid dendritic cells and B cells, synthetic CpG oligodeoxynucleotides (ODNs) trigger robust interferon-α production, dendritic cell maturation and cytotoxic T-lymphocyte activation. Preclinical studies have demonstrated that local delivery of CpG ODNs reshapes the tumour microenvironment, polarising macrophages toward a tumouricidal phenotype, reducing regulatory T-cell suppressive networks and enhancing antigen presentation. In parallel, strategies combining TLR9 agonists with immune checkpoint inhibitors, vaccines or in situ tumour-destruction techniques have raised the therapeutic ceiling for poorly immunogenic tumours. Advances in formulation—including nanoparticle carriers and liposomal antigens—have extended agonist half-life and targeted delivery, while intratumoural administration has emerged as critical for optimal efficacy. Collectively, these approaches underscore the global significance of TLR9 agonists as adjuvants and monotherapies in next-generation cancer immunotherapy.

Research from Nature Portfolio

Innovative work has demonstrated that ex vivo dendritic cell vaccines pulsed with low-dose liposomal peptide antigens and CpG ODN, when combined with PD-1 blockade, can overcome resistance in melanoma models. This regimen achieved a marked fourfold increase in intratumoural interferon-γ expression, elevated effector-to-regulatory T-cell ratios and significant tumour regression in both primary and distant sites. The synergy proved CD8+ T-cell dependent, yielding durable remissions and improved survival, and exemplifies how TLR9 agonists can be integrated into cellular vaccine platforms to potentiate checkpoint-based therapies.

Toll-Like Receptor 9 Agonist Applications in Cancer Immunotherapy publication trend

The graph below shows the total number of articles in toll-like receptor 9 agonist applications in cancer immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

Toll-like receptor 9 (TLR9): An endosomal pattern-recognition receptor that detects unmethylated CpG DNA motifs and initiates innate immune signalling.

CpG oligodeoxynucleotide (CpG ODN): A synthetic DNA fragment containing unmethylated CpG motifs designed to activate TLR9.

Plasmacytoid dendritic cell (pDC): A specialised dendritic cell subset that produces high levels of type I interferons upon TLR9 engagement.

Checkpoint blockade: Immunotherapy using antibodies to inhibit regulatory pathways (for example, PD-1/PD-L1) and reinvigorate T-cell responses.

Tumour microenvironment (TME): The complex milieu of stromal, immune and vascular cells surrounding a tumour, which influences therapeutic response.

References

1. CpG Oligonucleotides as Cancer Vaccine Adjuvants. Vaccines (2015).
2. Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice. PLOS ONE (2009).
3. Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. Frontiers in Immunology (2019).
4. Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy. Scientific Reports (2021).
5. Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II TrialSD-101 with Pembrolizumab in PD-1 Ab-Naïve SCCHN. Clinical Cancer Research (2022).
6. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discovery (2021).